Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
- Citation:
- Eur J Cancer vol 94 115-25
- Year:
- 2018
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Pharmas:
- Exelixis, Inc
- Grants:
- U10CA180821, U10CA180882, U10CA180791, U10CA180833, U10CA180850, U10CA180857, U10CA180867, P30 CA008748, U24176171
- Corr. Author:
- Authors:
- Toni K. Choueiri Colin Hessel Susan Halabi Ben Sanford M. Dror Michaelson Olwen Hahn Meghara Walsh Thomas Olencki Joel Picus Eric J. Small Shaker Dakhil Darren R. Feldman Milan Mangeshkar Christian Scheffold Daniel George Michael J. Morris
- Networks:
- CA136, KS055, LAPS-IL057, LAPS-MA036, LAPS-MO011, LAPS-NC010, LAPS-NY016, LAPS-OH007
- Study
- Alliance-A031203
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: